safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)10.30895/2312-7821-2026-14-2-127-130safetyrisk-584Research ArticleГЛАВНАЯ ТЕМА: ПСИХОТРОПНАЯ ТЕРАПИЯ И ФАРМАКОНАДЗОР: РИСКИ НЕЖЕЛАТЕЛЬНЫХ РЕАКЦИЙ, МЕТОДЫ ИХ ВЫЯВЛЕНИЯ И ПУТИ ПЕРСОНАЛИЗАЦИИMAIN TOPIC: PSYCHOTROPIC THERAPY AND PHARMACOVIGILANCE: RISKS OF ADVERSE REACTIONS, DETECTION METHODS, AND APPROACHES OF PERSONALIZATIONПсихотропные средства, статины и бета-блокаторы при беременности: новый фактор риска расстройств аутистического спектра у детей (анализ ретроспективного RWD/RWE-исследования)Psychotropic Agents, Statins, and Beta-Blockers in Pregnancy: A New Risk Factor for Autism Spectrum Disorders in Children (Analysis of a Retrospective RWD/RWE Study)https://orcid.org/0000-0002-4647-977XАляутдинР. Н.AlyautdinR. N.

Аляутдин Ренад Николаевич, д-р мед. наук, профессор

Петровский б-р, д. 8, стр. 2, Москва, 127051; Большая Пироговская ул., д. 2, стр. 4, Москва, 119048

Renad N. Alyautdin, Dr. Sci. (Med.), Professor

8/2 Petrovsky Blvd., Moscow 127051; 2/4 Bolshaya Pirogovskaya St., Moscow, 119048

alyautdin@expmed.ruФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации; Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияScientific Centre for Expert Evaluation of Medicinal Products; I.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202606072026142127130Copyright © Аляутдин Р.Н., 20262026Аляутдин Р.Н.Alyautdin R.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/584

Представлен авторский анализ главного редактора журнала «Безопасность и риск фармакотерапии» Аляутдина Р.Н. опубликованной в журнале Molecular Psychiatry статьи “Sterol pathway disruption in pregnancy: A link to autism” (2026 г.), в которой рассмотрены результаты масштабного ретроспективного RWD/RWE-исследования, охватившего более 6 млн пар «мать–дитя» (2014–2023 гг.). В исследовании выявлена связь пренатального воздействия ингибиторов постланостеролового синтеза холестерина с риском расстройств аутистического спектра у детей.

Editor-in-Chief of Safety and Risk of Pharmacotherapy Renad N. Alyautdin presents an analysis of the article “­Sterol pathway disruption in pregnancy: A link to autism” (2026), published in Molecular Psychiatry, which reports the results of a large-scale retrospective RWD/RWE study of more than 6 million mother–child pairs (2014–2023). The study identifies an association between prenatal exposure to inhibitors of post-lanosterol cholesterol synthesis and the risk of autism spectrum disorder in children.

фармаконадзорантипсихотикистатиныбета-блокаторыбеременностьстерольный гомеостазфармакогенетикаpharmacovigilanceantipsychotic agentsstatinsbeta-blockerspregnancysterol homeostasispharmacogeneticsРабота выполнена без спонсорской поддержкиThe study was performed without external fundingReferencesPeeples ES, Mirnics K, Korade Ž. Sterol pathway disruption in pregnancy: A link to autism. Mol Psychiatry. 2026. https://doi.org/10.1038/s41380-026-03610-7Peeples ES, Mirnics K, Korade Ž. Sterol pathway disruption in pregnancy: A link to autism. Mol Psychiatry. 2026. https://doi.org/10.1038/s41380-026-03610-7Korade Ž, Heffer M, Mirnics K. Medication effects on developmental sterol biosynthesis. Mol Psychiatry. 2022;27(1):490–501. https://doi.org/10.1038/s41380-021-01074-5Korade Ž, Heffer M, Mirnics K. Medication effects on developmental sterol biosynthesis. Mol Psychiatry. 2022;27(1):490–501. https://doi.org/10.1038/s41380-021-01074-5Korade Ž, Mirnics K. Sterol biosynthesis disruption by common prescription medications: critical implications for neural development and brain health. Brain Med. 2025. https://doi.org/10.61373/bm025p.0011Korade Ž, Mirnics K. Sterol biosynthesis disruption by common prescription medications: critical implications for neural development and brain health. Brain Med. 2025. https://doi.org/10.61373/bm025p.0011Lin J, De Rezende V, De Aguiar Da Costa M, et al. Cholesterol metabolism pathway in autism spectrum disorder: From animal models to clinical observations. Pharmacol Biochem Behav. 2023;223:173522. https://doi.org/10.1016/j.pbb.2023.173522Lin J, De Rezende V, De Aguiar Da Costa M, et al. Cholesterol metabolism pathway in autism spectrum disorder: From animal models to clinical observations. Pharmacol Biochem Behav. 2023;223:173522. https://doi.org/10.1016/j.pbb.2023.173522Aneja A, Tierney E. Autism: The role of cholesterol in treatment. Int Rev Psychiatry. 2008;20(2):165–70. https://doi.org/10.1080/09540260801889062Aneja A, Tierney E. Autism: The role of cholesterol in treatment. Int Rev Psychiatry. 2008;20(2):165–70. https://doi.org/10.1080/09540260801889062Schüle M, Butto T, Dewi S, et al. mTOR driven gene transcription is required for cholesterol production in neurons of the developing cerebral cortex. Int J Mol Sci. 2021;22(11):6034. https://doi.org/10.3390/ijms22116034Schüle M, Butto T, Dewi S, et al. mTOR driven gene transcription is required for cholesterol production in neurons of the developing cerebral cortex. Int J Mol Sci. 2021;22(11):6034. https://doi.org/10.3390/ijms22116034Peeples E, Mirnics K, Korade Ž. Chemical inhibition of sterol biosynthesis. Biomolecules. 2024;14(4):410. https://doi.org/10.3390/biom14040410Peeples E, Mirnics K, Korade Ž. Chemical inhibition of sterol biosynthesis. Biomolecules. 2024;14(4):410. https://doi.org/10.3390/biom14040410Kay H, Jang H, Kim I, Oh J. Pregnancy and neonatal outcomes after fetal exposure to statins among women with dyslipidemia: A nationwide cohort. Eur J Pediatr. 2025;184(6):340. https://doi.org/10.1007/s00431-025-06119-3Kay H, Jang H, Kim I, Oh J. Pregnancy and neonatal outcomes after fetal exposure to statins among women with dyslipidemia: A nationwide cohort. Eur J Pediatr. 2025;184(6):340. https://doi.org/10.1007/s00431-025-06119-3Edison R, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A. 2004;131(3):287–98. https://doi.org/10.1002/ajmg.a.30386Edison R, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A. 2004;131(3):287–98. https://doi.org/10.1002/ajmg.a.30386Esposito C, Buoli M, Ciappolino V, et al. The role of cholesterol and fatty acids in the etiology and diagnosis of autism spectrum disorders. Int J Mol Sci. 2021;22(7):3550. https://doi.org/10.3390/ijms22073550Esposito C, Buoli M, Ciappolino V, et al. The role of cholesterol and fatty acids in the etiology and diagnosis of autism spectrum disorders. Int J Mol Sci. 2021;22(7):3550. https://doi.org/10.3390/ijms22073550

The authors declare that there are no conflicts of interest present.